Generic Name

Briviact

Brand Names

for brivaracetam, an antiepileptic drug (AED) approved for adjunctive treatment of partial‑onset seizures in patients ≥2 years old. It is a highly selective synaptic vesicle protein 2A (SV2A) ligand that modulates presynaptic neurotransmitter release.

Mechanism

• High‑affinity SV2A modulation: Brivaracetam binds to SV2A with ~25‑30‑times higher affinity than levetiracetam, stabilizing presynaptic vesicle release and reducing excitatory neurotransmission.
• Non‑neuronal effects: Lack of affinity for CNS ion channels or receptors explains the low incidence of sedation and cognitive impairment compared with older AEDs.

---

Pharmacokinetics

• Absorption: Rapid oral bioavailability (≈95%); peak plasma at ~1 h.
• Distribution: Volume of distribution ~30 L/kg; negligible protein binding.
• Metabolism: Primarily through *cysteine conjugation* and *glucuronidation*; minimal CYP450 involvement.
• Elimination: Mean half‑life ~8.8 h; 75–80% excreted unchanged in urine.
• Drug–drug interaction profile: No clinically significant interactions with carbamazepine, phenytoin, valproate, or other AEDs.
• Special populations: No dose adjustment needed for hepatic impairment; mild adjustment for severe renal impairment (CrCl < 10 mL/min).

---

Indications

• Adjunctive therapy for partial‑onset seizures (with or without second‑arily generalized seizures).
• Adults and children ≥ 2 years (European guidelines) or ≥ 12 years (US FDA).

---

Contraindications

Contraindications
• Hypersensitivity to brivaracetam or any excipient.

Warnings
• Suicidal ideation/behavior: May exacerbate depression or anxiety. Monitor psychiatric status closely; discontinue if worsening.
• Pregnancy: Category D; risk of miscarriage and fetal anomalies. Avoid unless benefits outweigh risks—prefer alternative AEDs in pregnancy.
• Renal disease: Adjust for CrCl < 10 mL/min; avoid in dialysis patients unless alternative dosing.

---

Dosing

• Administration: Oral capsules, preferably with a meal if gastrointestinal upset occurs.
• Compliance tips: Consistent BID schedule; avoid abrupt discontinuation—gradual taper over 4–6 weeks.

--
•

Adverse Effects

Common (≥ 5% incidence)
• Dizziness, fatigue, somnolence
• Headache, nausea
• Mild rash or pruritus

Serious (rare)
• Hypersensitivity reaction (anaphylaxis, angioedema)
• Psychiatric destabilization (depression, suicidal ideation)
• Severe skin rash (Stevens–Johnson syndrome)

Monitoring of adverse effects
• Baseline eye exam and glucose levels not usually required.
• Routine follow‑up: seizure diary, weight, blood pressure (if hypertension suspected), mood.

---

Monitoring

• Seizure frequency: Document changes at each visit.
• Mood and behavior: Use validated scales (e.g., PHQ‑9, Columbia Suicide Severity Rating Scale).
• Weight: Track for appetite changes.
• Renal function: eGFR at baseline and annually (or after any acute renal insult).
• Drug levels: Not required; therapeutic drug monitoring not established.

---

Clinical Pearls

1. Higher SV2A affinity → less sedation: Brivaracetam often exhibits less somnolence than levetiracetam, making it suitable for patients requiring video‑EEG monitoring or daytime cognitive demands.

2. Lower interaction burden: Because metabolism is independent of CYP450, brivaracetam does not necessitate dose adjustment with carbamazepine or phenytoin—ideal for multi‑AED regimens.

3. Adjunctive over monotherapy: BLAKE study showed modest reduction in seizure frequency as adjunctive therapy; not currently approved as monotherapy.

4. Pediatric dosing uses body surface area: For children 2–11 y, weight‑based titration mirrors levetiracetam but with a higher target due to the greater SV2A potency.

5. Pregnancy risk profile: Data show increased miscarriage risk; thus, consider genetic counseling and contraception for women of childbearing potential.

6. Brivaracetam vs. Levetiracetam: If a patient tolerates levetiracetam poorly (e.g., excessive irritability), switching to Briviact may maintain efficacy with fewer behavioral side‑effects.

--
• Key takeaway: Briviact is a selective, well‑tolerated AED with a unique pharmacokinetic profile that allows safe combination with most other epilepsy medications, but requires vigilant monitoring for psychiatric side‑effects, especially in patients with pre‑existing mood disorders or pregnancy.